Skip to main content
. 2021 Dec 17;6(1):e677. doi: 10.1097/HS9.0000000000000677

Figure 1.

Figure 1.

Percentage of SARS-CoV-2 binding inhibition (NAbs) (A) and anti-S-RBD levels (B) for the study population. The asterisk (*) denotes a statistically significant difference between the ninth month levels and the previous timepoints (P < 0.05). The boxplot borders correspond to the distribution’s quartiles. NAbs = neutralizing antibodies; RBD = receptor binding domain.